Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Advisors
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Biomarker Capture Platform
SubB2M Pan-Cancer Probe
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Business Development
Products
Our Products
hTERT ICC Test
EXO-NET® Pan-Exosome
Product Technology & Features
Workflow and Performance
Product Ordering
Resources
Pipeline
Development Pipeline
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Conferences & Events
Media
INOVIQ in the News
Contact
Contact Us
Subscribe to Email Alerts
Analyst Reports
Heading &
Sub-heading can be edited through HQI
Investors
>
Analyst Reports
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Conferences & Events
Analyst Reports
13-Feb-2023
Good signs of progress in 2Q, SubB2M breast cancer study data
14-Dec-2022
OC97 study confirms EXO-NET utility for EV biomarker discovery
29-Nov-2022
EXO-NET kicks off in US; exosome work centralised in Melbourne
7-Nov-2022
MST Access: 1 1QFY23 closes with healthy cash balance
19-Oct-2022
MST Access: IIQ agrees to develop SubB2M test targeting pan-cancer diagnostic
25-Aug-2022
MST Access: Next-Gen Precision Diagnostics
